Continued access to catequentinib for prior study participants
Part of Cancer clinical trials.
This trial offers continued access to the study drug catequentinib (AL3818) for people who were already taking it in an earlier Advenchen study. It aims to see if you can keep benefiting from the treatment after the original trial ends.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be currently receiving the study drug (AL3818/catequentinib) from a prior Advenchen trial.
- Your most recent tumor check should show stable disease, shrinkage, or disappearance, or your doctor must believe you could still benefit if the disease has grown.
- You and your partner (if applicable) must agree to use effective birth control during the study and for 4 months after the last dose.
- You must be willing to sign a new consent form for this trial.
- You cannot have been off the study drug for more than 3 weeks when you start this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests two anti-cancer medicines (anlotinib and catequentinib) for people with certain advanced soft-tissue sarcomas, including alveolar soft part sarcoma, synovial sarcoma, and leiomyosarcoma. It is designed for tumors that cannot be removed and that have either grown despite treatment or no longer respond to standard options.
This study lets people who are already benefiting from the cancer drug tucatinib keep taking it after their original study ends. It aims to provide continued access to the treatment while monitoring safety and effectiveness.
This study lets people who are already taking alpelisib in another Novartis trial keep getting it after that trial ends. It checks long-term safety and continued benefit.
This study lets people who were already getting encorafenib and binimetinib in an earlier trial keep taking these medicines if they are doing well on them. It provides a way to continue treatment without a gap.
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
This trial tests different doses of a new drug (BI 3820768) in people with advanced solid tumors, specifically germ cell tumors, endometrial cancer, or ovarian cancer. The goal is to see if the drug is safe and how well it works.
Hear when a new Gynecologic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.